BioCentury | Feb 8, 2020
Politics, Policy & Law

GAO finds little evidence Priority Review program spurring drug development

There is little evidence that the U.S. rare pediatric disease Priority Review voucher program has incentivized development of medicines, according to a Government Accountability Office report . The report could influence Congress, which is facing a...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jul 27, 2018
Clinical News

FDA committee: 60 Degrees' malaria candidate safe and effective

...FDA approved Krintafel tafenoquine, an 8-aminoquinoline derivative, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the not-for-profit Medicines for Malaria Venture...
BioCentury | Jul 27, 2018
Clinical News

FDA approves GSK's Krintafel to prevent malaria relapse

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse...
...NYSE:GSK), London, U.K. Product: Krintafel tafenoquine Business: Infectious Jaime De Leon Krintafel, tafenoquine (TQ, SB 252263, WR-238605) GlaxoSmithKline plc Medicines for Malaria Venture...
BioCentury | Jul 26, 2018
Company News

FDA committee: 60 Degrees' malaria candidate safe and effective

...FDA approved Krintafel tafenoquine, an 8-aminoquinoline derivative, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the not-for-profit Medicines for Malaria Venture...
BioCentury | Jul 20, 2018
Company News

FDA approves Krintafel to prevent malaria relapse

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse...
...designation. The product is also under review in Australia. Jaime De Leon TQ, tafenoquine (SB 252263, WR-238605) GlaxoSmithKline plc Medicines for Malaria Venture Krintafel...
BioCentury | Jul 13, 2018
Clinical News

FDA panel votes in favor of GSK's malaria candidate

...U.S. proprietary name for tafenoquine is Krintafel. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
BioCentury | Jun 29, 2018
Clinical News

FDA panel to discuss GSK’s malaria candidate

...derivative, has breakthrough therapy designation from FDA. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
BioCentury | Jun 25, 2018
Company News

FDA panel to discuss GSK’s malaria candidate

...derivative, has breakthrough therapy designation from FDA. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
...MMV), submitted the NDA in November. The product is also under review in Australia. Meghan Sullivan tafenoquine GlaxoSmithKline plc Medicines for Malaria Venture...
BioCentury | Dec 1, 2017
Company News

Astellas, MMV partner to identify antimalarial compounds

...Astellas Pharma Inc. (Tokyo:4503) and Medicines for Malaria Venture (Geneva, Switzerland) partnered to identify antimalarial candidates. MMV will work...
...Tokyo, Japan Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Allison Johnson Astellas Pharma Inc. Global Health Innovative Technology (GHIT) Fund Griffith University Medicines for Malaria Venture...
Items per page:
1 - 10 of 114
BioCentury | Feb 8, 2020
Politics, Policy & Law

GAO finds little evidence Priority Review program spurring drug development

There is little evidence that the U.S. rare pediatric disease Priority Review voucher program has incentivized development of medicines, according to a Government Accountability Office report . The report could influence Congress, which is facing a...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jul 27, 2018
Clinical News

FDA committee: 60 Degrees' malaria candidate safe and effective

...FDA approved Krintafel tafenoquine, an 8-aminoquinoline derivative, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the not-for-profit Medicines for Malaria Venture...
BioCentury | Jul 27, 2018
Clinical News

FDA approves GSK's Krintafel to prevent malaria relapse

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse...
...NYSE:GSK), London, U.K. Product: Krintafel tafenoquine Business: Infectious Jaime De Leon Krintafel, tafenoquine (TQ, SB 252263, WR-238605) GlaxoSmithKline plc Medicines for Malaria Venture...
BioCentury | Jul 26, 2018
Company News

FDA committee: 60 Degrees' malaria candidate safe and effective

...FDA approved Krintafel tafenoquine, an 8-aminoquinoline derivative, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the not-for-profit Medicines for Malaria Venture...
BioCentury | Jul 20, 2018
Company News

FDA approves Krintafel to prevent malaria relapse

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse...
...designation. The product is also under review in Australia. Jaime De Leon TQ, tafenoquine (SB 252263, WR-238605) GlaxoSmithKline plc Medicines for Malaria Venture Krintafel...
BioCentury | Jul 13, 2018
Clinical News

FDA panel votes in favor of GSK's malaria candidate

...U.S. proprietary name for tafenoquine is Krintafel. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
BioCentury | Jun 29, 2018
Clinical News

FDA panel to discuss GSK’s malaria candidate

...derivative, has breakthrough therapy designation from FDA. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
BioCentury | Jun 25, 2018
Company News

FDA panel to discuss GSK’s malaria candidate

...derivative, has breakthrough therapy designation from FDA. GSK, which is developing tafenoquine with the not-for-profit Medicines for Malaria Venture...
...MMV), submitted the NDA in November. The product is also under review in Australia. Meghan Sullivan tafenoquine GlaxoSmithKline plc Medicines for Malaria Venture...
BioCentury | Dec 1, 2017
Company News

Astellas, MMV partner to identify antimalarial compounds

...Astellas Pharma Inc. (Tokyo:4503) and Medicines for Malaria Venture (Geneva, Switzerland) partnered to identify antimalarial candidates. MMV will work...
...Tokyo, Japan Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Allison Johnson Astellas Pharma Inc. Global Health Innovative Technology (GHIT) Fund Griffith University Medicines for Malaria Venture...
Items per page:
1 - 10 of 114